References
- Diehl V, Engert A, Re D. New strategies for the treatment of advanced-stage Hodgkin's lymphoma. Hem Oncol Clin N Am 2007; 21: 897–914
- Bartlett N L, Rosenberg S A, Hoppe R T, Hancock S L, Horning S J. Brief chemotherapy, Stanford V and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J Clin Oncol 1995; 13: 1080–1088
- Horning S J, Williams J, Bartlett N L, et al. Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group Pilot Study E1492. J Clin Oncol 2000; 18: 972–980
- Aversa S ML, Salvagno L, Sorar[ugrave] M, et al. Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's disease. Acta Haematol 2004; 112: 141–147
- Abuzetun J, Loberizia F, Vose J, et al. The Stanford V regimen is effective in patients with good risk Hodgkin lymphoma but radiotherapy is a necessary component. Br J Haematol 2009; 144: 531–537
- Avvisati G, Lo Coco F, Diverio D, et al. AIDA (all-trans retinoic acid + idarubucina) in newly diagnostic acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood 1996; 88: 1390–1398
- Pedersen-Bjergaard J, Klarskov Andersen M, Johansson B. Balanced chromosome aberrations in leukemia following chemotherapy with DNA-topoisomerase II inhibitors. J Clin Oncol 1998; 16: 1897–1898
- Mistry A R, Felix C A, Whitmarsh R J, et al. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med 2005; 352: 1529–1538
- Swerdlow A J, Barber J A, Hudson G V, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 2000; 18: 498–509
- Hoffmann L, Moller P, Pedersen-Bjergaard J, et al. Therapy related acute promyelocytic leukemia with t(15,17)(q22,q12) following chemotherapy with drugs targeting DNA topoisomerase II: a report of two cases and a review of the literature. Ann Oncol 1995; 6: 781–788
- Hershman D, Neugut A I, Jacobson J S, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colonystimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007; 99: 196–205
- Freedman M H, Bonilla M A, Fier C, et al. Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy. Blood 2000; 96: 429–436
- Patt D A, Duan Z, Fang S, Hortobagyi G N, Giordano S H. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol 2000; 25: 3871–3876
- Smith R E, Bryant J, DeCillis A, Anderson S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin- cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 2003; 21: 1195–1204
- Pulsoni A, Pagano L, Lo Coco F, et al. Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumour: the GIMEMA experience. Blood 2002; 100: 1972–1976